Concord Biotech Limited

₹612.20As of Sun 8 Nov 2026, 12:00 UTC
NSE:CONCORDBIOHealthcare
Country India
PE (Fwd) •••
TSR 3Y CAGR 8.04%
Div yield 0.62%
ROE 14.33%
Biotechnology
Beta (5Y) 0.44
PE TTM 45.57
TSR TTM (14.69%)
Mkt cap ₹128.1B
ROIC 15.85%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹720
17.63%
(92.44%)
Hold 10|9|12|6|12
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
7.61
8.50
9.10
9.51
14.63%
23.87%
33.42%
39.56%
Revenue₹B
10.84
10.63
11.18
11.79
5.09%
2.26%
3.47%
8.62%
Peers (US$1.399B)
Cap (US$)
PE
1.124B
34.63x
596.2M
31.61x
1.389B
6.637x
Capital
TTM
5Y
10Y
Leveragex
0.912
0.140
0.113
EBIT/Intx
0.588
0.104
0.087
Own earn%
196.65
(65.34)
(73.22)
Sh yield%
16.12
13.54
14.07
Owners
Insiders/Inst%
3.14
44.29
Short interest%
2.48
SBC / revenue%
3.75
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
6–10
$1 testx
0.7
Incr. ROIC%
11